Basit öğe kaydını göster

dc.contributor.authorTopuz, Erkan
dc.contributor.authorTas, Faruk
dc.contributor.authorDerin, Duygu
dc.contributor.authorGuney, Nese
dc.contributor.authorAydiner, Adnan
dc.date.accessioned2021-03-03T11:48:46Z
dc.date.available2021-03-03T11:48:46Z
dc.date.issued2008
dc.identifier.citationTas F., Guney N., Derin D., Aydiner A., Topuz E., "A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.2, ss.156-160, 2008
dc.identifier.issn1341-9625
dc.identifier.otherav_2a1c3435-5e75-449d-93d7-22ece3ce4347
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/33101
dc.identifier.urihttps://doi.org/10.1007/s10147-007-0740-4
dc.description.abstractBackground. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleA pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer
dc.typeMakale
dc.relation.journalINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume13
dc.identifier.issue2
dc.identifier.startpage156
dc.identifier.endpage160
dc.contributor.firstauthorID187067


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster